Table 1.
Clinical characteristics in relation to hospitalization, ICU admission and death.
| All patients (n = 60) | Requiring hospitalization (n = 46) | ICU admission (n = 11) | Death (n = 14) | |
|---|---|---|---|---|
| Median age, years (range) | 71 (43–97) | 71 (43–97) | 71 (50–76) | 81 (43–97) |
| ≥75 y | 32% (19/60) | 35% (16/46) | 18% (2/11) | 57% (8/14) |
| Male | 65% (39/60) | 70% (32/46) | 64% (7/11) | 64% (9/14) |
| CIRS median (range) (n = 60) | 8 (4–20) | 9 (4–20) | 8 (4–17) | 10 (4–20) |
| CIRS > 6 | 75% (45/60) | 80% (37/46) | 73% (8/11) | 86% (12/14) |
| BMI, median (range) (n = 49) | 25 (19–42) | 25 (20–42) | 25 (23–30) | 24 (20–30) |
| Diabetes | 30% (18/60) | 30% (14/46) | 36% (4/11) | 14% (2/14) |
| Never smoker | 53% (31/59) | 50% (23/46) | 45% (5/11) | 50% (7/14) |
| IgG (g/L), median (range) | 7.9 (2.1–13.4) | 8.3 (2.1–13.4) | 8.3 (5.8–9.6) | 5.4 (2.1–10.6) |
| CLL treatment at Covid-19 diagnosis (n = 60) | ||||
| Never treated | 63% (38/60) | 63% (29/46) | 55% (6/11) | 64% (9/14) |
| Previously treateda | 20% (12/60) | 15% (7/46) | 9% (1/11) | 7% (1/14) |
| Ongoing therapyb | 17% (10/60) | 22% (10/46) | 36% (4/11) | 29% (4/14) |
| Current BTKi | 70% (7/10) | 70% (7/10) | 50% (2/4) | 75% (3/4) |
| CLL status at Covid-19 diagnosis (n = 60) | ||||
| SD | 63% (38/60) | 70% (32/46) | 64% (7/11) | 64% (9/14) |
| CR/PR | 25% (15/60) | 22% (10/46) | 27% (3/11) | 36% (5/14) |
| PD | 12% (7/60) | 8% (4/46) | 9% (1/11) | 0% (0/14) |
aAll >12 months ago.
bone patient received venetoclax; one patient received venetoclax + rituximab; one patient received bendamustin + rituximab; seven patients received BTKi.